69 results on '"Maughan T"'
Search Results
2. Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer
- Author
-
Corry, SM, McCorry, AMB, Lannagan, TRM, Leonard, NA, Fisher, NC, Byrne, RM, Tsantoulis, P, Cortes-Lavaud, X, Amirkhah, R, Redmond, KL, McCooey, AJ, Malla, SB, Rogan, E, Sakhnevych, S, Gillespie, MA, White, M, Richman, SD, Jackstadt, R-F, Campbell, AD, Maguire, S, S:CORT and ACRCelerate consortia, McDade, SS, Longley, DB, Loughrey, MB, Coleman, HG, Kerr, EM, Tejpar, S, Maughan, T, Leedham, SJ, Small, DM, Ryan, AE, Sansom, OJ, Lawler, M, and Dunne, PD
- Abstract
Objective Stroma-rich tumours represent a poor prognostic subtype in stage II/III colon cancer (CC), with high relapse rates and limited response to standard adjuvant chemotherapy. Design To address the lack of efficacious therapeutic options for patients with stroma-rich CC, we stratified our human tumour cohorts according to stromal content, enabling identification of the biology underpinning relapse and potential therapeutic vulnerabilities specifically within stroma-rich tumours that could be exploited clinically. Following human tumour-based discovery and independent clinical validation, we use a series of in vitro and stroma-rich in vivo models to test and validate the therapeutic potential of elevating the biology associated with reduced relapse in human tumours. Results By performing our analyses specifically within the stroma-rich/high-fibroblast (HiFi) subtype of CC, we identify and validate the clinical value of a HiFi-specific prognostic signature (HPS), which stratifies tumours based on STAT1-related signalling (High-HPS v Low-HPS=HR 0.093, CI 0.019 to 0.466). Using in silico, in vitro and in vivo models, we demonstrate that the HPS is associated with antigen processing and presentation within discrete immune lineages in stroma-rich CC, downstream of double-stranded RNA and viral response signalling. Treatment with the TLR3 agonist poly(I:C) elevated the HPS signalling and antigen processing phenotype across in vitro and in vivo models. In an in vivo model of stroma-rich CC, poly(I:C) treatment significantly increased systemic cytotoxic T cell activity (p
- Published
- 2022
3. Validation of high-performance low-field-strength T1-weighted neuroimaging sequence modelling
- Author
-
Whyntie, T, Chu, K, Dhanda, V, Hughes, D, Patel, T, Teoh, S, and Maughan, T
- Published
- 2021
4. Association analyses identify 31 new risk loci for colorectal cancer susceptibility
- Author
-
Law, PJ, Timofeeva, M, Fernandez-Rozadilla, C, Broderick, P, Studd, J, Fernandez-Tajes, J, Farrington, S, Svinti, V, Palles, C, Orlando, G, Sud, A, Holroyd, A, Penegar, S, Theodoratou, E, Vaughan-Shaw, P, Campbell, H, Zgaga, L, Hayward, C, Campbell, A, Harris, S, Deary, IJ, Starr, J, Gatcombe, L, Pinna, M, Briggs, S, Martin, L, Jaeger, E, Sharma-Oates, A, East, J, Leedham, S, Arnold, R, Johnstone, E, Wang, H, Kerr, D, Kerr, R, Maughan, T, Kaplan, R, Al-Tassan, N, Palin, K, Hänninen, UA, Cajuso, T, Tanskanen, T, Kondelin, J, Kaasinen, E, Sarin, A-P, Eriksson, JG, Rissanen, H, Knekt, P, Pukkala, E, Jousilahti, P, Salomaa, V, Ripatti, S, Palotie, A, Renkonen-Sinisalo, L, Lepistö, A, Böhm, J, Mecklin, J-P, Buchanan, DD, Win, A-K, Hopper, J, Jenkins, ME, Lindor, NM, Newcomb, PA, Gallinger, S, Duggan, D, Casey, G, Hoffmann, P, Nöthen, MM, Jöckel, K-H, Easton, DF, Pharoah, PDP, Peto, J, Canzian, F, Swerdlow, A, Eeles, RA, Kote-Jarai, Z, Muir, K, Pashayan, N, Consortium, Practical, Harkin, A, Allan, K, McQueen, J, Paul, J, Iveson, T, Saunders, M, Butterbach, K, Chang-Claude, J, Hoffmeister, M, Brenner, H, Kirac, I, Matošević, P, Hofer, P, Brezina, S, Gsur, A, Cheadle, JP, Aaltonen, LA, Tomlinson, I, Houlston, RS, Dunlop, MG, Law, Philip J [0000-0001-9663-4611], Timofeeva, Maria [0000-0002-2503-4253], Fernandez-Rozadilla, Ceres [0000-0001-7330-4804], Broderick, Peter [0000-0002-8348-5829], Studd, James [0000-0002-7157-754X], Farrington, Susan [0000-0001-5955-7389], Svinti, Victoria [0000-0001-9926-0416], Sud, Amit [0000-0002-6133-0164], Hayward, Caroline [0000-0002-9405-9550], Campbell, Archie [0000-0003-0198-5078], Martin, Lynn [0000-0003-3962-389X], East, James [0000-0001-8035-3700], Kaplan, Richard [0000-0002-0189-8348], Al-Tassan, Nada [0000-0001-9076-0334], Palin, Kimmo [0000-0002-4621-6128], Salomaa, Veikko [0000-0001-7563-5324], Buchanan, Daniel D [0000-0003-2225-6675], Win, Aung-Ko [0000-0002-2794-5261], Jenkins, Mark E [0000-0002-8964-6160], Easton, Douglas F [0000-0003-2444-3247], Pharoah, Paul DP [0000-0001-8494-732X], Eeles, Rosalind A [0000-0002-3698-6241], Muir, Kenneth [0000-0001-6429-988X], Pashayan, Nora [0000-0003-0843-2468], Harkin, Andrea [0000-0002-8831-7381], Paul, James [0000-0001-7367-5816], Hofer, Philipp [0000-0003-2550-6019], Brezina, Stefanie [0000-0001-5238-6900], Cheadle, Jeremy P [0000-0001-9453-8458], Tomlinson, Ian [0000-0003-3037-1470], Houlston, Richard S [0000-0002-5268-0242], and Apollo - University of Cambridge Repository
- Subjects
Male ,Science ,Inheritance Patterns ,cancer genetics ,Datasets as Topic ,colorectal cancer ,Genome-wide association studies ,Polymorphism, Single Nucleotide ,Article ,White People ,Asian People ,Risk Factors ,Cancer genomics ,Humans ,Genetic Predisposition to Disease ,lcsh:Science ,Cancer genetics ,neoplasms ,cancer genomics ,genomiikka ,Middle Aged ,Colorectal cancer ,digestive system diseases ,peräsuolisyöpä ,syöpägeenit ,Genetic Loci ,Case-Control Studies ,genome-wide association studies ,lcsh:Q ,syöpätaudit ,Female ,Colorectal Neoplasms ,Genome-Wide Association Study - Abstract
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, and has a strong heritable basis. We report a genome-wide association analysis of 34,627 CRC cases and 71,379 controls of European ancestry that identifies SNPs at 31 new CRC risk loci. We also identify eight independent risk SNPs at the new and previously reported European CRC loci, and a further nine CRC SNPs at loci previously only identified in Asian populations. We use in situ promoter capture Hi-C (CHi-C), gene expression, and in silico annotation methods to identify likely target genes of CRC SNPs. Whilst these new SNP associations implicate target genes that are enriched for known CRC pathways such as Wnt and BMP, they also highlight novel pathways with no prior links to colorectal tumourigenesis. These findings provide further insight into CRC susceptibility and enhance the prospects of applying genetic risk scores to personalised screening and prevention., In colorectal cancer (CRC), finding loci associated with risk may give insight into disease aetiology. Here, the authors report a genome-wide association analysis in Europeans of 34,627 CRC cases and 71,379 controls, and find 31 new risk loci and 17 new risk SNPs at previously reported loci.
- Published
- 2019
5. Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons
- Author
-
Hague, D, Townsend, S, Masters, L, Rauchenberger, M, Van Looy, N, Diaz-Montana, C, Gannon, M, James, N, Maughan, T, Parmar, MKB, Brown, L, Sydes, MR, and Investigators, Stampede And Focus4
- Subjects
Male ,Adaptive trials ,Data management ,Medicine (miscellaneous) ,Database design ,Database ,03 medical and health sciences ,Random Allocation ,0302 clinical medicine ,Resource (project management) ,Case report form ,Medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Randomisation ,Trial conduct ,Protocol (science) ,Clinical Trials as Topic ,lcsh:R5-920 ,Data collection ,Early stopping ,business.industry ,Methodology ,Prostatic Neoplasms ,Interim analysis ,Data science ,Clinical trials unit ,Research Design ,business ,Colorectal Neoplasms ,lcsh:Medicine (General) ,Platform protocol ,030217 neurology & neurosurgery ,Multi-arm multi-stage (MAMS) - Abstract
Background There is limited research and literature on the data management challenges encountered in multi-arm, multi-stage platform and umbrella protocols. These trial designs allow both (1) seamless addition of new research comparisons and (2) early stopping of accrual to individual comparisons that do not show sufficient activity. FOCUS4 (colorectal cancer) and STAMPEDE (prostate cancer), run from the Medical Research Council Clinical Trials Unit (CTU) at UCL, are two leading UK examples of clinical trials implementing adaptive platform protocol designs. To date, STAMPEDE has added five new research comparisons, closed two research comparisons following pre-planned interim analysis (lack of benefit), adapted the control arm following results from STAMPEDE and other relevant trials, and completed recruitment to six research comparisons. FOCUS4 has closed one research comparison following pre-planned interim analysis (lack of benefit) and added one new research comparison, with a number of further comparisons in the pipeline. We share our experiences from the operational aspects of running these adaptive trials, focusing on data management. Methods We held discussion groups with STAMPEDE and FOCUS4 CTU data management staff to identify data management challenges specific to adaptive platform protocols. We collated data on a number of case report form (CRF) changes, database amendments and database growth since each trial began. Discussion We found similar adaptive protocol-specific challenges in both trials. Adding comparisons to and removing them from open trials provides extra layers of complexity to CRF and database development. At the start of an adaptive trial, CRFs and databases must be designed to be flexible and scalable in order to cope with the continuous changes, ensuring future data requirements are considered where possible. When adding or stopping a comparison, the challenge is to incorporate new data requirements while ensuring data collection within ongoing comparisons is unaffected. Some changes may apply to all comparisons; others may be comparison-specific or applicable only to patients recruited during a specific time period. We discuss the advantages and disadvantages of the different approaches to CRF and database design we implemented in these trials, particularly in relation to use and maintenance of generic versus comparison-specific CRFs and databases. The work required to add or remove a comparison, including the development and testing of changes, updating of documentation, and training of sites, must be undertaken alongside data management of ongoing comparisons. Adequate resource is required for these competing data management tasks, especially in trials with long follow-up. A plan is needed for regular and pre-analysis data cleaning for multiple comparisons that could recruit at different rates and periods of time. Data-cleaning activities may need to be split and prioritised, especially if analyses for different comparisons overlap in time. Conclusions Adaptive trials offer an efficient model to run randomised controlled trials, but setting up and conducting the data management activities in these trials can be operationally challenging. Trialists and funders must plan for scalability in data collection and the resource required to cope with additional competing data management tasks. Electronic supplementary material The online version of this article (10.1186/s13063-019-3322-7) contains supplementary material, which is available to authorized users.
- Published
- 2019
- Full Text
- View/download PDF
6. Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial
- Author
-
Adams, R, Fisher, D, Graham, J, Seligmann, JF, Seymour, M, Kaplan, RS, Yates, E, Richman, SD, Quirke, P, Butler, R, Brown, E, Falk, S, Collinson, FJ, Wilson, RH, Brown, LC, and Maughan, T
- Abstract
3504 Background: There is extensive randomised evidence supporting the use of treatment breaks in mCRC, but breaks from treatment are not universally offered to patients despite reductions in toxicity, without detriment to OS. Prior trials have shown that the combination of Cp and bevacizumab extend PFS but not OS. FOCUS4-N explores oral maintenance Cp monotherapy in patients with disease control on first line therapy. Methods: FOCUS4 was a molecularly stratified trial programme registering patients with newly diagnosed mCRC from 88 hospitals in the UK. Whilst undergoing 16 wks of first line treatment, a sample of tumour was sent for laboratory testing to stratify their disease into molecular subtypes: MSI, BRAF, PIK3CA, TP53 and RAS mutations. For some molecular groups, a targeted therapy subtrial was available but entry into the FOCUS4-N trial was offered to those in whom a targeted subtrial was unavailable. Patients were randomised 1:1 between maintenance Cp therapy or AM. The primary outcome was PFS assessed using 8-wkly RECIST reported CT scans with quality of life (using EQ5D 8 weekly) and OS as secondary outcomes. Toxicity and tolerability were assessed 4-wkly. On progression, from the nadir, patients recommenced first line treatment. Cox regression was used to assess efficacy by intention-to-treat (ITT) with adjustment for tumour location, WHO status, metastatic burden, first line treatment and biomarker subtype. Results: Between March 2014 and March 2020, 254 patients were randomised (127 to Cp and 127 to AM). Baseline characteristics were balanced between groups but event rates were higher than anticipated in the AM group and the final analysis was triggered early as a result of the COVID-19 pandemic halting recruitment. The table presents results for PFS and OS. Compliance with treatment was good with per-protocol analysis results very similar to ITT (PFS HR=0.38 (95% CI 0.28-0.51)). Toxicity from Cp v AM was as expected with G≥2 fatigue (25% v 12%), diarrhoea (23% v 13%) and hand-foot syndrome (26% v 3%). Quality of life showed no statistically significant differences between the two arms. Conclusions: Despite strong evidence of prolongation of PFS with maintenance therapy, OS remains unaffected and FOCUS4-N provides additional evidence to support the use of treatment breaks as a safe management alternative for patients who are stable or responding well to first line treatment for mCRC. Cp without bevacizumab may be used to extend PFS, in the interval after 16 weeks of combination therapy. Clinical trial information: ISRCTN#90061546. [Table: see text]
- Published
- 2021
7. Image-based consensus molecular subtype classification (imCMS) of colorectal cancer using deep learning
- Author
-
Sirinukunwattana, K, Domingo-Villanueva, E, Richman, S, Blake, A, Verrill, C, Leedham, SJ, Wu, C-H, Maughan, T, Rittscher, J, and Koelzer, VH
- Abstract
Objective: Complex phenotypes captured on histological slides represent the biological processes at play in individual cancers but the link to underlying molecular classification has not been clarified or systematised. In colorectal cancer (CRC), histological grading is a poor predictor of disease progression, and consensus molecular subtypes (CMS) cannot be distinguished without gene expression profiling. We hypothesise that image analysis is a cost-effective tool to associate complex features of tissue organisation with molecular and outcome data and to resolve unclassifiable or heterogeneous cases. In this study, we present an image-based approach to predict CRC CMS from standard H&E sections using deep learning. Design: Training and evaluation of a neural network were performed using a total of n=1,206 tissue sections with comprehensive multi-omic data from three independent datasets (training on FOCUS trial, n=278 patients; test on rectal cancer biopsies, GRAMPIAN cohort, n=144 patients, and The Cancer Genome Atlas (TCGA), n=430 patients). Ground truth CMS calls were ascertained by matching random forest and single sample predictions from MSclassifier. Results: Image-based CMS (imCMS) accurately classified slides in unseen datasets from TCGA (n=431 slides, AUC=0.84) and rectal cancer biopsies (n=265 slides, AUC=0.85). imCMS spatially resolved intra-tumoural heterogeneity and provided secondary calls correlating with bioinformatic prediction from molecular data. imCMS classified samples previously unclassifiable by RNA expression profiling, reproduced the expected correlations with genomic and epigenetic alterations and showed similar prognostic associations as transcriptomic CMS. Conclusion: This study shows that a prediction of RNA expression classifiers can be made from H&E images, opening the door to simple, cheap and reliable biological stratification within routine workflows.
- Published
- 2020
8. Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification
- Author
-
Dunne, P, Alderdice, M, O'Reilly, P, Roddy, A, McCorry, A, Richman, S, Maughan, T, McDade, S, Johnston, P, Longley, D, Kay, E, McArt, D, and Lawler, M
- Subjects
Gene Expression Profiling ,Science ,Prognosis ,Article ,Cohort Studies ,Gene Expression Regulation, Neoplastic ,SDG 3 - Good Health and Well-being ,Lymphatic Metastasis ,Biomarkers, Tumor ,Humans ,Lymph Nodes ,Neoplasm Metastasis ,Colorectal Neoplasms ,Transcriptome ,Algorithms ,Oligonucleotide Array Sequence Analysis - Abstract
Stromal-derived intratumoural heterogeneity (ITH) has been shown to undermine molecular stratification of patients into appropriate prognostic/predictive subgroups. Here, using several clinically relevant colorectal cancer (CRC) gene expression signatures, we assessed the susceptibility of these signatures to the confounding effects of ITH using gene expression microarray data obtained from multiple tumour regions of a cohort of 24 patients, including central tumour, the tumour invasive front and lymph node metastasis. Sample clustering alongside correlative assessment revealed variation in the ability of each signature to cluster samples according to patient-of-origin rather than region-of-origin within the multi-region dataset. Signatures focused on cancer-cell intrinsic gene expression were found to produce more clinically useful, patient-centred classifiers, as exemplified by the CRC intrinsic signature (CRIS), which robustly clustered samples by patient-of-origin rather than region-of-origin. These findings highlight the potential of cancer-cell intrinsic signatures to reliably stratify CRC patients by minimising the confounding effects of stromal-derived ITH., Tumour expression profiling is currently used for prognostic and predictive purposes without taking into account the intra patient heterogeneity. Here the authors show that cancer cell specific signatures overcome the tumour heterogeneity effect and result in better classification of colorectal cancer patients.
- Published
- 2017
- Full Text
- View/download PDF
9. A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS
- Author
-
Gollins, S, West, N, Sebag-Montefiore, D, Susnerwala, S, Falk, S, Brown, N, Saunders, M, Quirke, P, Ray, R, Parsons, P, Griffiths, G, Maughan, T, Adams, R, Hurt, C, and McIntyre, A
- Abstract
BACKGROUND:Neoadjuvant chemotherapy (NAC) allows earlier treatment of rectal cancer micro-metastases but is not standard of care. There are currently no biomarkers predicting long-term progression-free survival (PFS) benefit from NAC. PATIENTS AND METHODS:In this single arm phase II trial, patients with non-metastatic magnetic resonance imaging (MRI)-defined operable rectal adenocarcinoma at high risk of post-operative metastatic recurrence, received 8 weeks of oxaliplatin/fluorouracil NAC then short-course preoperative radiotherapy (SCPRT) before immediate surgery. Sixteen weeks of post-operative adjuvant chemotherapy (AC) was planned. A pelvic MRI was performed at week 9 immediately post-NAC, before SCPRT. The primary end point was feasibility assessed by completion of protocol treatment up to and including surgery. Secondary endpoints included compliance, toxicity, downstaging efficacy, and PFS. RESULTS:In total 60 patients were recruited May 2012-June 2014. In total 57 patients completed protocol treatment, meeting the primary endpoint. Compliance with NAC was much better than AC: Comparing NAC vs. AC, the median percentage dose intensity for fluoropyrimidine was 100% vs. 63% and for oxaliplatin 100% vs. 45%. Treatment-related toxicity was acceptable with no treatment-related deaths. Post-NAC MRI showed 44 tumours (73%) were T-downstaged and 22 (37%) had excellent MRI tumour regression grade (mrTRG 1-2). Median follow-up was 27 months with 2-year PFS of 86.2% (10 events). On exploratory analysis, post-NAC mrTRG predicted PFS with no event among those with excellent regression. CONCLUSION:The regimen was well tolerated with effective downstaging and encouraging PFS. mrTRG response to NAC may be a new prognostic factor for long-term PFS, but needs validation in larger studies.
- Published
- 2019
10. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database
- Author
-
Franko, J, Shi, Q, Meyers, J, Maughan, T, Adams, R, Seymour, M, Saltz, L, Punt, C, Koopman, M, Tournigand, C, Tebbutt, N, Diaz-Rubio, E, Souglakos, J, Falcone, A, Chibaudel, B, Heinemann, V, Moen, J, De Gramont, A, Sargent, D, Grothey, A, Group, Analysis And Research In Cancers Of The Digestive System (Arcad), and Oncology
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Adolescent ,Colorectal cancer ,Clinical Trial, Phase III ,Rectum ,Metastasis ,law.invention ,03 medical and health sciences ,Phase III ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,Journal Article ,medicine ,Clinical endpoint ,Humans ,Prospective Studies ,Prospective cohort study ,Peritoneal Neoplasms ,Aged ,Proportional Hazards Models ,Aged, 80 and over ,Proportional hazards model ,business.industry ,Middle Aged ,Prognosis ,medicine.disease ,Clinical Trial ,Clinical trial ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Randomized Controlled Trial ,Female ,030211 gastroenterology & hepatology ,Colorectal Neoplasms ,business - Abstract
BACKGROUND: Patients with peritoneal metastatic colorectal cancer have reduced overall survival compared with patients with metastatic colorectal cancer without peritoneal involvement. Here we further investigated the effect of the number and location of metastases in patients receiving first-line systemic chemotherapy. METHODS: We analysed individual patient data for previously untreated patients enrolled in 14 phase 3 randomised trials done between 1997 and 2008. Trials were included if protocols explicitly pre-specified and solicited for patients with peritoneal involvement in the trial data collection process or had done a formal peritoneum-focused review of individual pre-treatment scans. We used stratified multivariable Cox models to assess the prognostic associations of peritoneal metastatic colorectal cancer with overall survival and progression-free survival, adjusting for other key clinical-pathological factors (age, sex, Eastern Cooperative Oncology Group (ECOG) performance score, primary tumour location [colon vs rectum], previous treatment, and baseline BMI). The primary endpoint was difference in overall survival between populations with and without peritoneal metastases. FINDINGS: Individual patient data were available for 10 553 patients. 9178 (87%) of 10 553 patients had non-peritoneal metastatic colorectal cancer (4385 with one site of metastasis, 4793 with two or more sites of metastasis), 194 (2%) patients had isolated peritoneal metastatic colorectal cancer, and 1181 (11%) had peritoneal metastatic colorectal cancer and other organ involvement. These groups were similar in age, ethnic origin, and use of targeted treatment. Patients with peritoneal metastatic colorectal cancer were more likely than those with non-peritoneal metastatic colorectal cancer to be women (565 [41%] of 1371 vs 3312 [36%] of 9169 patients; p=0·0003), have colon primary tumours (1116 [84%] of 1334 patients vs 5603 [66%]; p
- Published
- 2019
- Full Text
- View/download PDF
11. Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies
- Author
-
Alderdice, M, Richman, S, Gollins, S, Stewart, J, Hurt, C, Adams, R, McCorry, A, Roddy, A, Vimalachandran, D, Isella, C, Medico, E, Maughan, T, McArt, D, Lawler, M, and Dunne, P
- Subjects
Original Paper ,molecular stratification ,transcriptional signatures ,consensus molecular subtypes ,colorectal cancer ,Original Papers ,Gene Expression Regulation, Neoplastic ,SDG 3 - Good Health and Well-being ,Colonic Neoplasms ,Biomarkers, Tumor ,Journal Article ,gene expression profiling ,Humans ,biopsy ,intrinsic subtypes ,Prospective Studies ,Colorectal Neoplasms ,Neoplasm Staging - Abstract
Colorectal cancer (CRC) biopsies underpin accurate diagnosis, but are also relevant for patient stratification in molecularly‐guided clinical trials. The consensus molecular subtypes (CMSs) and colorectal cancer intrinsic subtypes (CRISs) transcriptional signatures have potential clinical utility for improving prognostic/predictive patient assignment. However, their ability to provide robust classification, particularly in pretreatment biopsies from multiple regions or at different time points, remains untested. In this study, we undertook a comprehensive assessment of the robustness of CRC transcriptional signatures, including CRIS and CMS, using a range of tumour sampling methodologies currently employed in clinical and translational research. These include analyses using (i) laser‐capture microdissected CRC tissue, (ii) eight publically available rectal cancer biopsy data sets (n = 543), (iii) serial biopsies (from AXEBeam trial, NCT00828672; n = 10), (iv) multi‐regional biopsies from colon tumours (n = 29 biopsies, n = 7 tumours), and (v) pretreatment biopsies from the phase II rectal cancer trial COPERNCIUS (NCT01263171; n = 44). Compared to previous results obtained using CRC resection material, we demonstrate that CMS classification in biopsy tissue is significantly less capable of reliably classifying patient subtype (43% unknown in biopsy versus 13% unknown in resections, p = 0.0001). In contrast, there was no significant difference in classification rate between biopsies and resections when using the CRIS classifier. Additionally, we demonstrated that CRIS provides significantly better spatially‐ and temporally‐ robust classification of molecular subtypes in CRC primary tumour tissue compared to CMS (p = 0.003 and p = 0.02, respectively). These findings have potential to inform ongoing biopsy‐based patient stratification in CRC, enabling robust and stable assignment of patients into clinically‐informative arms of prospective multi‐arm, multi‐stage clinical trials. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
- Published
- 2019
- Full Text
- View/download PDF
12. FMISO-PET and perfusion CT at baseline and week 2 CRT as predictive markers for response in rectal cancer
- Author
-
Greenhalgh, T, Wilson, J, Puri, T, Franklin, J, Wang, L, Goldin, R, Chu, K, Strauss, V, Partridge, M, and Maughan, T
- Published
- 2019
13. Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: a phase I study in patients with advanced non-small cell lung carcinoma
- Author
-
McGowan, D, Skwarski, M, Bradley, K, Campo, L, Fenwick, J, Gleeson, F, Green, M, Horne, A, Maughan, T, McCole, M, Mohammed, S, Muschel, R, Ng, S, Panakis, N, Prevo, R, Strauss, V, Stuart, R, Tacconi, E, Vallis, K, McKenna, W, Macpherson, R, and Higgins, G
- Subjects
Male ,Radiation-Sensitizing Agents ,Lung Neoplasms ,Maximum Tolerated Dose ,Morpholines ,Aminopyridines ,Adenocarcinoma of Lung ,PI3K inhibitor ,NSCLC ,Article ,Phase I trial ,Carcinoma, Non-Small-Cell Lung ,Positron Emission Tomography Computed Tomography ,Humans ,Misonidazole ,Tumour hypoxia ,Fatigue ,Aged ,Phosphoinositide-3 Kinase Inhibitors ,FMISO PET-CT ,Radiotherapy ,Nausea ,Chemoradiotherapy ,Middle Aged ,Anorexia ,Carcinoma, Squamous Cell ,Tumor Hypoxia ,Female - Abstract
Background\udPre-clinically, phosphoinositide 3-kinase (PI3K) inhibition radiosensitises tumours by increasing intrinsic radiosensitivity and by reducing tumour hypoxia. We assessed whether buparlisib, a class 1 PI3K inhibitor, can be safely combined with radiotherapy in patients with non-small cell lung carcinoma (NSCLC) and investigated its effect on tumour hypoxia.\udMethods\udThis was a 3 + 3 dose escalation and dose expansion phase I trial in patients with advanced NSCLC. Buparlisib dose levels were 50 mg, 80 mg and 100 mg once daily orally for 2 weeks, with palliative thoracic radiotherapy (20 Gy in 5 fractions) delivered during week 2. Tumour hypoxic volume (HV) was measured using 18F-fluoromisonidazole positron-emission tomography–computed tomography at baseline and following 1 week of buparlisib.\udResults\udTwenty-one patients were recruited with 9 patients evaluable for maximum tolerated dose (MTD) analysis. No dose-limiting toxicity was reported; therefore, 100 mg was declared the MTD, and 10 patients received this dose in the expansion phase. Ninety-four percent of treatment-related adverse events were ≤grade 2 with fatigue (67%), nausea (24%) and decreased appetite (19%) most common per patient. One serious adverse event (grade 3 hypoalbuminaemia) was possibly related to buparlisib. No unexpected radiotherapy toxicity was reported. Ten (67%) of 15 patients evaluable for imaging analysis were responders with 20% median reduction in HV at the MTD.\udConclusion\udThis is the first clinical trial to combine a PI3K inhibitor with radiotherapy in NSCLC and investigate the effects of PI3K inhibition on tumour hypoxia. This combination was well tolerated and PI3K inhibition reduced hypoxia, warranting investigation into whether this novel class of radiosensitisers can improve radiotherapy outcomes.
- Published
- 2019
14. Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine +/- nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)
- Author
-
Strauss, V, Shaw, R, Virdee, P, Hurt, C, Ward, E, Tranter, B, Patel, N, Bridgewater, J, Parsons, P, Radhakrishna, G, O’Neill, E, Sebag-Montefiore, D, Hawkins, M, Corrie, P, Maughan, T, and Mukherjee, S
- Subjects
Adult ,Male ,Adolescent ,Antineoplastic Agents ,Adenocarcinoma ,Radiation Dosage ,lcsh:RC254-282 ,Young Adult ,Study Protocol ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Capecitabine ,Aged ,Aged, 80 and over ,Nelfinavir ,Gemcitabine and nab-paclitaxel (GEMABX) ,Neoplasms, Second Primary ,Chemoradiotherapy ,Induction Chemotherapy ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Combined Modality Therapy ,Survival Analysis ,Pancreatic Neoplasms ,Treatment Outcome ,Chemoradiation ,Female ,Locally advanced pancreatic cancer (LAPC) - Abstract
Background Induction chemotherapy followed by chemoradiation is a treatment option for patients with locally advanced pancreatic cancer (LAPC). However, overall survival is comparable to chemotherapy alone and local progression occurs in nearly half of all patients, suggesting chemoradiation strategies should be optimised. SCALOP-2 is a randomised phase II trial testing the role of radiotherapy dose escalation and/or the addition of the radiosensitiser nelfinavir, following induction chemotherapy of gemcitabine and nab-paclitaxel (GEMABX). A safety run-in phase (stage 1) established the nelfinavir dose to administer with chemoradiation in the randomised phase (stage 2). Methods Patients with locally advanced, inoperable, non-metastatic pancreatic adenocarcinoma receive three cycles of induction GEMABX chemotherapy prior to radiological assessment. Those with stable/responding disease are eligible for further trial treatment. In Stage 1, participants received one further cycle of GEMABX followed by capecitabine-chemoradiation with escalating doses of nelfinavir in a rolling-six design. Stage 2 aims to register 262 and randomise 170 patients with responding/stable disease to one of five arms: capecitabine with high- (arms C + D) or standard-dose (arms A + B) radiotherapy with (arms A + C) or without (arms B + D) nelfinavir, or three more cycles of GEMABX (arm E). Participants allocated to the chemoradiation arms receive another cycle of GEMABX before chemoradiation begins. Co-primary outcomes are 12-month overall survival (radiotherapy dose-escalation question) and progression-free survival (nelfinavir question). Secondary outcomes include toxicity, quality of life, disease response rate, resection rate, treatment compliance, and CA19–9 response. SCALOP-2 incorporates a detailed radiotherapy quality assurance programme. Discussion SCALOP-2 aims to optimise chemoradiation in LAPC and incorporates a modern induction regimen. Trial registration Eudract No: 2013–004968-56; ClinicalTrials.gov: NCT02024009.
- Published
- 2019
15. A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS
- Author
-
Gollins, S, West, N, Sebag-Montefiore, D, Susnerwala, S, Falk, S, Brown, N, Saunders, M, Quirke, P, Ray, R, Parsons, P, Griffiths, G, Maughan, T, Adams, R, Hurt, C, and McIntyre, A
- Subjects
Adult ,Male ,Rectal Neoplasms ,Radiotherapy Dosage ,Middle Aged ,Combined Modality Therapy ,Survival Analysis ,Drug Administration Schedule ,Neoadjuvant Therapy ,Article ,Oxaliplatin ,Treatment Outcome ,Chemotherapy, Adjuvant ,Feasibility Studies ,Humans ,Patient Compliance ,Female ,Radiotherapy, Adjuvant ,Fluorouracil ,Prospective Studies ,Rectal cancer ,Aged ,Neoplasm Staging - Abstract
Background: Neoadjuvant chemotherapy (NAC) allows earlier treatment of rectal cancer micro-metastases but is not standard of care. There are currently no biomarkers predicting long-term progression-free survival (PFS) benefit from NAC. Patients and methods: In this single arm phase II trial, patients with non-metastatic magnetic resonance imaging (MRI)-defined operable rectal adenocarcinoma at high risk of post-operative metastatic recurrence, received 8 weeks of oxaliplatin/fluorouracil NAC then short-course preoperative radiotherapy (SCPRT) before immediate surgery. Sixteen weeks of post-operative adjuvant chemotherapy (AC) was planned. A pelvic MRI was performed at week 9 immediately post-NAC, before SCPRT. The primary end point was feasibility assessed by completion of protocol treatment up to and including surgery. Secondary endpoints included compliance, toxicity, downstaging efficacy, and PFS. Results: In total 60 patients were recruited May 2012–June 2014. In total 57 patients completed protocol treatment, meeting the primary endpoint. Compliance with NAC was much better than AC: Comparing NAC vs. AC, the median percentage dose intensity for fluoropyrimidine was 100% vs. 63% and for oxaliplatin 100% vs. 45%. Treatment-related toxicity was acceptable with no treatment-related deaths. Post-NAC MRI showed 44 tumours (73%) were T-downstaged and 22 (37%) had excellent MRI tumour regression grade (mrTRG 1–2). Median follow-up was 27 months with 2-year PFS of 86.2% (10 events). On exploratory analysis, post-NAC mrTRG predicted PFS with no event among those with excellent regression. Conclusion: The regimen was well tolerated with effective downstaging and encouraging PFS. mrTRG response to NAC may be a new prognostic factor for long-term PFS, but needs validation in larger studies.
- Published
- 2018
16. SCALOP-2: A randomised trial of induction GEMABX followed by chemoradiation (high/standard dose radiation) +/-nelfinavir for locally advanced pancreatic cancer: results of the dose-finding component
- Author
-
Mukherjee, S, Virdee, P, Shaw, R, Bridgewater, J, Radhakrishna, G, Falk, S, Scott-Brown, M, Strauss, V, Brookes, C, Gillmore, R, Patel, N, Tranter, B, Parsons, P, Sebag-Montefiore, S, Hawkins, M, Corrie, P, and Maughan, T
- Abstract
The anti-retroviral agent, nelfinavir, demonstrates radiosensitising effects in pre-clinical models of pancreatic cancer. The primary objective of Stage 1 was to establish the maximum tolerated dose (MTD) of nelfinavir combined with capecitabine-chemoradiation (CRT) after gemcitabine+nab-paclitaxel (GEMABX) induction chemotherapy. Other outcomes included overall survival and progression-free survival.
- Published
- 2018
17. Safety and tumour hypoxia modifying effect of buparlisib with radiotherapy in NSCLC: a phase I dose escalation study
- Author
-
Skwarski, M, McGowan, DR, Bradley, KM, Fenwick, JD, Gleeson, FV, Horne, A, Maughan, T, McKenna, WG, Mohammed, S, Muschel, RJ, Ng, SM, Panakis, N, Strauss, VY, Stuart, R, Vallis, KA, Macpherson, RE, and Higgins, GS
- Published
- 2018
- Full Text
- View/download PDF
18. Functional parameters derived from magnetic resonance imaging reflect vascular 1 morphology in preclinical tumors and in human liver metastases
- Author
-
Kannan, P, Kretzschmar, W, Winter, H, Warren, D, Bates, R, Allen, P, Syed, N, Irving, B, Papiez, B, Kaeppler, J, Markelc, B, Kinchesh, P, Gilchrist, S, Smart, S, Schnabel, J, Maughan, T, Harris, A, Muschel, R, Partridge, M, Sharma, R, and Kersemans, V
- Abstract
Purpose: Tumor vessels influence the growth and response of tumors to therapy. Imaging vascular changes in vivo using dynamic contrast-enhanced MRI (DCE-MRI) has shown potential to guide clinical decision making for treatment. However, quantitative MR imaging biomarkers of vascular function have not been widely adopted, partly because their relationship to structural changes in vessels remains unclear. We aimed to elucidate the relationships between vessel function and morphology in vivo. Experimental Design: Untreated preclinical tumors with different levels of vascularization were imaged sequentially using DCE-MRI and CT. Relationships between functional parameters from MR (iAUC, Ktrans, and BATfrac) and structural parameters from CT (vessel volume, radius, and tortuosity) were assessed using linear models. Tumors treated with anti-VEGFR2 antibody were then imaged to determine whether antiangiogenic therapy altered these relationships. Finally, functional–structural relationships were measured in 10 patients with liver metastases from colorectal cancer. Results: Functional parameters iAUC and Ktrans primarily reflected vessel volume in untreated preclinical tumors. The relationships varied spatially and with tumor vascularity, and were altered by antiangiogenic treatment. In human liver metastases, all three structural parameters were linearly correlated with iAUC and Ktrans. For iAUC, structural parameters also modified each other's effect. Conclusions: Our findings suggest that MR imaging biomarkers of vascular function are linked to structural changes in tumor vessels and that antiangiogenic therapy can affect this link. Our work also demonstrates the feasibility of three-dimensional functional–structural validation of MR biomarkers in vivo to improve their biological interpretation and clinical utility.
- Published
- 2018
19. Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial
- Author
-
Adams, R, Brown, E, Brown, L, Butler, R, Falk, S, Fisher, D, Kaplan, R, Quirke, P, Richman, S, Samuel, L, Seligmann, J, Seymour, M, Shiu, KK, Wasan, H, Wilson, R, Maughan, T, and FOCUS4 Trial Investigators
- Abstract
Background: A substantial change in trial methodology for solid tumours has taken place, in response to increased understanding of cancer biology. FOCUS4 is a phase 2–3 trial programme testing targeted agents in patients with advanced colorectal cancer in molecularly stratified cohorts. Here, we aimed to test the hypothesis that combined inhibition of EGFR, HER2, and HER3 signalling with the tyrosine kinase inhibitor AZD8931 will control growth of all wild-type tumours.\ud \ud \ud \ud Methods: In FOCUS4-D, we included patients from 18 hospitals in the UK with newly diagnosed advanced or metastatic colorectal cancer whose tumour was wild-type for BRAF, PIK3CA, KRAS, and NRAS. After 16 weeks of first-line therapy, patients with stable or responding tumours were randomised to oral AZD8931 (40 mg twice a day) or placebo. Randomisation was done by minimisation with a random element of 20%, minimisation by hospital site, site of primary tumour, WHO performance status, 16-week CT scan result, number of metastatic sites, and first-line chemotherapy regimen. The primary outcome was progression-free-survival. CT scans were assessed by local radiologists according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Preplanned interim analyses were assessed per protocol and were agreed using multiarm multistage (MAMS) trial design methodology triggered by occurrence of progression-free survival events in the placebo group. The final analysis was assessed by intention to treat. This trial is registered at , ISRCTN 90061546.\ud \ud \ud \ud Findings: Between July 7, 2014, and March 7, 2016, 32 patients were randomised to study treatment, 16 to AZD8931 and 16 to placebo. At the first preplanned interim analysis (March, 2016), the independent data monitoring committee (IDMC) recommended closure of FOCUS4-D because of a lack of activity. At the final analysis (Aug 1, 2016), 31 patients had had a progression-free survival event (15 with AZD8931 and 16 with placebo). Median progression-free survival was 3·48 months (95% CI 1·51–5·09) in the placebo group and 2·96 months (1·94–5·62) in the AZD8931 group. No progression-free survival benefit of AZD8931 compared with placebo was noted (hazard ratio [HR] 1·10, 95% CI 0·47–3·57; p=0·95). The most common grade 3 adverse event in the AZD8931 group was skin rash (three [20%] of 15 patients with available data vs none of 16 patients in the placebo group), and in the placebo group it was diarrhoea (one [7%] vs one [6%]). No grade 4 adverse events were recorded and no treatment-related deaths were reported.\ud \ud \ud \ud Interpretation: The MAMS trial design for FOCUS4 has shown efficiency and effectiveness in trial outcome delivery, informing the decision to proceed or stop clinical evaluation of a targeted treatment within a molecularly defined cohort of patients. The overarching FOCUS4 trial is now aiming to open a replacement arm in the cohort with all wild-type tumours.\ud \ud \ud \ud Funding: Medical Research Council (MRC) and National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation programme, Cancer Research UK, NIHR Clinical Trials Research Network, Health and Care Research Wales, and AstraZeneca.
- Published
- 2018
20. The evolutionary landscape of colorectal tumorigenesis
- Author
-
Cross, W., Kovac, M., Mustonen, V., Temko, D., Davis, H., Baker, A.-M., Biswas, S., Arnold, R., Chegwidden, L., Gatenbee, C., Anderson, A.R., Koelzer, V.H., Martinez, P., Jiang, X., Domingo, E., Woodcock, D.J., Feng, Y., Kovacova, M., Maughan, T., Adams, R., Bach, S., Beggs, A., Brown, L., Buffa, F., Cazier, J.-B., Blake, A., Wu, C.-H., Chatzpili, E., Richman, S., Dunne, P., Harkin, P., Higgins, G., Hill, J., Holmes, C., Horgan, D., Kaplan, R., Kennedy, R., Lawler, M., Leedham, S., McDermott, U., McKenna, G., Middleton, G., Morton, D., Murray, G., Quirke, P., Salto-Tellez, M., Samuel, L., Schuh, A., Sebag-Montefiore, D., Seymour, M., Sharma, R., Sullivan, R., Tomlinson, I., West, N., Wilson, R., Jansen, M., Rodriguez-Justo, M., Ashraf, S., Guy, R., Cunningham, C., East, J.E., Wedge, D.C., Wang, L.M., Palles, C., Heinimann, K., Sottoriva, A., Graham, T.A., and Tomlinson, I.P.M.
- Subjects
0301 basic medicine ,Adenoma ,Fitness landscape ,Carcinogenesis ,Evolutionary landscape ,Biology ,medicine.disease_cause ,Models, Biological ,Article ,Evolution, Molecular ,03 medical and health sciences ,medicine ,Humans ,Stabilizing selection ,Ecology, Evolution, Behavior and Systematics ,Exome sequencing ,Ecology ,Manchester Cancer Research Centre ,Genetic heterogeneity ,ResearchInstitutes_Networks_Beacons/mcrc ,Carcinoma ,Cancer ,medicine.disease ,030104 developmental biology ,Evolutionary biology ,Mutation ,Colorectal Neoplasms - Abstract
The evolutionary events that cause colorectal adenomas (benign) to progress to carcinomas (malignant) remain largely undetermined. Using multi-region genome/exome sequencing of 24 benign and malignant colorectal tumours, we probe the evolutionary fitness landscape occupied by these neoplasms. Unlike carcinomas, advanced adenomas frequently harbour sub-clonal driver mutations, which are considered to be functionally important in the carcinogenic process, that have not swept to fixation, and have relatively high genetic heterogeneity. Carcinomas are distinguished from adenomas by widespread aneusomies that are usually clonal and often accrue in a “punctuated” fashion. We conclude that adenomas evolve across an undulating fitness landscape, whereas carcinomas occupy a sharper fitness peak, probably owing to stabilising selection.
- Published
- 2018
- Full Text
- View/download PDF
21. Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET)
- Author
-
Harrington, K, Hall, E, Hawkins, M, Henry, A, MacKay, R, Maughan, T, McDonald, A, Nutting, C, Oelfke, U, Sebag-Montefiore, D, Sharma, RA, van Herk, M, Faivre-Finn, C, and ART-NET Steering Committee
- Published
- 2017
22. P-233: SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer
- Author
-
Virdee, P, Shaw, R, Strauss, V, Hamill, C, Hurt, C, Gwynne, S, Corrie, P, Bridgewater, J, Parsons, P, Tranter, B, Sebag-Montefiore, D, Chu, K, Radhakrishna, G, Hawkins, M, O'Neill, E, Campbell, S, Love, S, Maughan, T, and Mukherjee, S
- Abstract
hemotherapy followed by consolidation chemoradiotherapy (CRT) is a treatment option for locally advanced non-metastatic pancreatic cancer (LAPC), but outcome remains poor. The SCALOP trial identified a feasible, safe, and effective CRT regimen for LAPC: capecitabine (830mg/m2 oral bd) as radiosensitisation + 50.4Gy in 28 fractions. The two-stage SCALOP-2 trial aims to improve this regimen by increasing radiotherapy dose intensity and adding nelfinavir as an additional radiosensitising AKT inhibitor.
- Published
- 2017
23. Phylogenetic ctDNA analysis depicts early stage lung cancer evolution
- Author
-
Abbosh, C, Birkbak, NJ, Wilson, GA, Jamal-Hanjani, M, Constantin, T, Salari, R, Quesne, JL, Moore, DA, Veeriah, S, Rosenthal, R, Marafioti, T, Kirkizlar, E, Watkins, TBK, McGranahan, N, Ward, S, Martinson, L, Riley, J, Fraioli, F, Bakir, MA, GrÖnroos, E, Zambrana, F, Endozo, R, Bi, WL, Fennessy, FM, Sponer, N, Johnson, D, Laycock, J, Shafi, S, Czyzewska-Khan, J, Rowan, A, Chambers, T, Matthews, N, Turajlic, S, Hiley, C, Lee, SM, Forster, MD, Ahmad, T, Falzon, M, Borg, E, Lawrence, D, Hayward, M, Kolvekar, S, Panagiotopoulos, N, Janes, SM, Thakrar, R, Ahmed, A, Blackhall, F, Summers, Y, Hafez, D, Naik, A, Ganguly, A, Kareht, S, Shah, R, Joseph, L, Quinn, AM, Crosbie, P, Naidu, B, Middleton, G, Langman, G, Trotter, S, Nicolson, M, Remmen, H, Kerr, K, Chetty, M, Gomersall, L, Fennell, DA, Nakas, A, Rathinam, S, Anand, G, Khan, S, Russell, P, Ezhil, V, Ismail, B, Irvin-sellers, M, Prakash, V, Lester, JF, Kornaszewska, M, Attanoos, R, Adams, H, Davies, H, Oukrif, D, Akarca, AU, Hartley, JA, Lowe, HL, Lock, S, Iles, N, Bell, H, Ngai, Y, Elgar, G, Szallasi, Z, Schwarz, RF, Herrero, J, Stewart, A, Quezada, SA, Van Loo, P, Dive, C, Lin, CJ, Rabinowitz, M, Aerts, HJWL, Hackshaw, A, Shaw, JA, Zimmermann, BG, Swanton, C, Bosshard-Carter, L, Goh, G, Gorman, P, Murugaesu, N, Hynds, RE, Wilson, G, Horswell, S, Al Bakir, M, Mitter, R, Escudero, M, Xu, H, Goldman, J, Stone, RK, Denner, T, Biggs, J, Costa, M, Begum, S, Phillimore, B, Nye, E, Graca, S, Joshi, K, Furness, A, Aissa, AB, Wong, YNS, Georgiou, A, Quezada, S, Simeon, C, Hector, G, Smith, A, Aranda, M, Novelli, M, Forster, M, Papadatos-Pastos, D, Carnell, D, Mendes, R, George, J, Navani, N, Taylor, M, Choudhary, J, Califano, R, Taylor, P, Krysiak, P, Rammohan, K, Fontaine, E, Booton, R, Evison, M, Moss, S, Idries, F, Bishop, P, Chaturved, A, Marie Quinn, A, Doran, H, leek, A, Harrison, P, Moore, K, Waddington, R, Novasio, J, Rogan, J, Smith, E, Tugwood, J, Brady, G, Rothwell, DG, Chemi, F, Pierce, J, Gulati, S, Bellamy, M, Bancroft, H, Kerr, A, Kadiri, S, Webb, J, Djearaman, M, Fennell, D, Le Quesne, J, Moore, D, Thomas, A, Walter, H, Monteiro, W, Marshall, H, Nelson, L, Bennett, J, Primrose, L, Amadi, A, Palmer, S, Miller, J, Buchan, K, Lester, J, Edwards, A, Morgan, F, Verjee, A, MacKenzie, M, Wilcox, M, Smith, S, Gower, N, Ottensmeier, C, Chee, S, Johnson, B, Alzetani, A, Shaw, E, Lim, E, De Sousa, P, Tavares Barbosa, M, Bowman, A, Jordan, S, Rice, A, Raubenheimer, H, Proli, C, Elena Cufari, M, Ronquillo, JC, Kwayie, A, Bhayani, H, Hamilton, M, Bakar, Y, Mensah, N, Ambrose, L, Devaraj, A, Buderi, S, Finch, J, Azcarate, L, Chavan, H, Green, S, Mashinga, H, Nicholson, AG, Lau, K, Sheaff, M, Schmid, P, Conibear, J, Light, T, Horey, T, Danson, S, Bury, J, Edwards, J, Hill, J, Matthews, S, Kitsanta, Y, Suvarna, K, Fisher, P, Keerio, AD, Shackcloth, M, Gosney, J, Postmus, P, Feeney, S, Asante-Siaw, J, Constatin, T, Zimmermann, B, Dentro, S, Dessimoz, C, Shiu, K-K, Bridgewater, J, Hochauser, D, Beck, S, Parker, P, Walczak, H, Enver, T, Proctor, I, Sinclair, R, Lok, C-W, Mitchison, M, Trevisan, G, Lynch, M, Brandner, S, Gishen, F, Tookman, A, Stone, P, Sterling, C, Larkin, J, Attard, G, Eeles, R, Foster, C, Bova, S, Sottoriva, A, Chowdhury, S, Ashish, C, Spicer, J, Stares, M, Lynch, J, Caldas, C, Brenton, J, Fitzgerald, R, Jimenez-Linan, M, Provenzano, E, Cluroe, A, Stewart, G, Watts, C, Gilbertson, R, McDermott, U, Tavare, S, Maughan, T, Tomlinson, I, Campbell, P, McNeish, I, Biankin, A, Chambers, A, Fraser, S, Oien, K, Krebs, M, Marais, R, Carter, L, Nonaka, D, Dhomen, N, Shaw, J, Baijal, S, Tanchel, B, Collard, M, Cockcroft, P, Taylor, J, Colloby, P, Olisemeke, B, Wilson, R, Harrison, D, Loda, M, Flanagan, A, McKenzie, M, Lederman, J, Sharp, A, and Farrelly, L
- Subjects
0301 basic medicine ,Oncology ,Lung Neoplasms ,IMPACT ,Biopsy ,DNA Mutational Analysis ,Drug resistance ,Metastasis ,0302 clinical medicine ,Limit of Detection ,Carcinoma, Non-Small-Cell Lung ,Medicine ,Neoplasm Metastasis ,Early Detection of Cancer ,Multidisciplinary ,medicine.diagnostic_test ,Phylogenetic tree ,DNA, Neoplasm ,STATISTICS ,3. Good health ,Tumor Burden ,Multidisciplinary Sciences ,Cell Tracking ,PEACE consortium ,030220 oncology & carcinogenesis ,Disease Progression ,Science & Technology - Other Topics ,medicine.medical_specialty ,CARCINOMA ,Tumour heterogeneity ,General Science & Technology ,Early detection ,Evolution, Molecular ,03 medical and health sciences ,Internal medicine ,MD Multidisciplinary ,Carcinoma ,Humans ,Cell Lineage ,Lung cancer ,Postoperative Care ,Science & Technology ,MUTATIONS ,TRACERx consortium ,business.industry ,CIRCULATING TUMOR DNA ,Reproducibility of Results ,medicine.disease ,R1 ,NEGATIVE BREAST-CANCER ,Clone Cells ,030104 developmental biology ,Drug Resistance, Neoplasm ,UPTAKE RATIO ,Immunology ,FDG PET ,Neoplasm Recurrence, Local ,business ,Multiplex Polymerase Chain Reaction - Abstract
The early detection of relapse following primary surgery for non-small-cell lung cancer and the characterization of emerging subclones, which seed metastatic sites, might offer new therapeutic approaches for limiting tumour recurrence. The ability to track the evolutionary dynamics of early-stage lung cancer non-invasively in circulating tumour DNA (ctDNA) has not yet been demonstrated. Here we use a tumour-specific phylogenetic approach to profile the ctDNA of the first 100 TRACERx (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy (Rx)) study participants, including one patient who was also recruited to the PEACE (Posthumous Evaluation of Advanced Cancer Environment) post-mortem study. We identify independent predictors of ctDNA release and analyse the tumour-volume detection limit. Through blinded profiling of postoperative plasma, we observe evidence of adjuvant chemotherapy resistance and identify patients who are very likely to experience recurrence of their lung cancer. Finally, we show that phylogenetic ctDNA profiling tracks the subclonal nature of lung cancer relapse and metastasis, providing a new approach for ctDNA-driven therapeutic studies.
- Published
- 2017
24. Depletion of Signal Recognition Particle 72kDa increases radiosensitivity
- Author
-
Prevo, R, Tiwana, G, Maughan, T, Buffa, F, McKenna, W, and Higgins, G
- Abstract
The identification of genetic determinants that underpin tumor radioresistance can help the development of targeted radiosensitizers or aid personalization of radiotherapy treatment. Here we identify signal recognition particle 72kDa (SRP72) as a novel gene involved in radioresistance. Knockdown of SRP72 resulted in significant radiosensitization of HeLa (cervical), PSN-1 (pancreatic), and T24 (bladder), BT-549 (breast) and MCF7 (breast) tumor lines as measured by colony formation assays. SRP72 depletion also resulted in the radiosensitization of normal lung fibroblast cell lines (HFL1 and MRC-5), demonstrating that the effect is not restricted to tumor cells. Increased radiosensitivity was not due to impaired DNA damage signaling or repair as assessed by γ-H2AX foci formation. Instead SRP72 depletion was associated with elevated levels of apoptosis after irradiation, as measured by caspase 3/7 activity, PARP-cleavage and Annexin-V staining, and with an induction of the unfolded protein response. Together, our results show that SRP72 is a novel gene involved in radioresistance.
- Published
- 2017
25. SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer
- Author
-
Virdee, P, Shaw, R, Strauss, V, Hamill, C, Hurt, C, Corrie, P, Bridgewater, J, Parsons, P, Tranter, B, Sebag-Montefiore, D, Chu, K, Radhakrishna, G, Hawkins, M, O'Neill, E, Campbell, S, Love, S, Maughan, T, and Mukherjee, S
- Abstract
Chemotherapy followed by consolidation chemoradiotherapy (CRT) is a treatment option for locally advanced non-metastatic pancreatic cancer (LAPC), but outcome remains poor. The SCALOP trial identified a feasible, safe, and effective CRT regimen for LAPC: capecitabine (830mg/m2 oral bd) as radiosensitisation + 50.4Gy in 28 fractions. The two-stage SCALOP-2 trial aims to improve this regimen by increasing radiotherapy dose intensity and adding nelfinavir as an additional radiosensitising AKT inhibitor.
- Published
- 2017
26. Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/? cetuximab in oesophageal cancer
- Author
-
Crosby, T, Hurt, C, Falk, S, Gollins, S, Staffurth, J, Ray, R, Bridgewater, J, Geh, J, Cunningham, D, Blazeby, J, Roy, R, Maughan, T, Griffiths, G, and Mukherjee, S
- Subjects
Male ,Esophageal Neoplasms ,oesophageal ,Cetuximab ,Chemoradiotherapy ,Adenocarcinoma ,trial ,Prognosis ,R1 ,Survival Rate ,Antineoplastic Combined Chemotherapy Protocols ,Carcinoma, Squamous Cell ,Clinical Study ,Humans ,phase II/III ,Female ,Neoplasm Invasiveness ,Cisplatin ,Neoplasm Recurrence, Local ,randomised ,Capecitabine ,Aged ,Follow-Up Studies ,Neoplasm Staging - Abstract
Background: The SCOPE-1 study tested the role of adding cetuximab to conventional definitive chemoradiotherapy (dCRT), and\ud demonstrated greater toxicity and worse survival outcomes. We present the long-term outcomes and patterns of recurrence.\ud Methods: SCOPE-1 was a phase II/III trial in which patients were randomised to cisplatin 60mgm�2 (day 1) and capecitabine\ud 625mgm�2 bd (days 1–21) for four cycles þ/� cetuximab 400mgm�2 day 1 then by 250mgm�2 weekly. Radiotherapy\ud consisted of 50 Gy/25# given concurrently with cycles 3 and 4. Recruitment was between February 2008 and February 2012, when\ud the IDMC recommended closure on the basis of futility.\ud Results: About 258 patients (dCRT¼129; dCRTþcetuximab (dCRTþC)¼129) were recruited from 36 centres. About 72.9%\ud (n¼188) had squamous cell histology. The median follow-up (IQR) was 46.2 (35.9–48.3) months for surviving patients. The median\ud overall survival (OS; months; 95% CI) was 34.5 (24.7–42.3) in dCRT and 24.7 (18.6–31.3) in dCRTþC (hazard ratio (HR)¼1.25, 95%\ud CIs: 0.93–1.69, P¼0.137). Median progression-free survival (PFS; months; 95% CI) was 24.1 (15.3–29.9) and 15.9 (10.7–20.8) months,\ud respectively (HR¼1.28, 95% CIs: 0.94–1.75; P¼0.114). On multivariable analysis only earlier stage, full-dose RT, and higher\ud cisplatin dose intensity were associated with improved OS.\ud Conclusions: The mature analysis demonstrates that the dCRT regimen used in the study provided useful survival outcomes\ud despite its use in patients who were largely unfit for surgery or who had inoperable disease. Given the competing risk of systemic\ud and local failure, future studies should continue to focus on enhancing local control as well as optimising systemic therapy.
- Published
- 2017
27. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer
- Author
-
Hurt, C, Falk, S, Crosby, A, MacDonald, A, Ray, R, Joseph, G, Staffurth, J, Abrams, R, Griffiths, G, Maughan, T, and Mukherjee, S
- Subjects
RC0254 - Abstract
background: SCALOP, a randomised, phase II trial, tested the activity and safety of gemcitabine (GEM)-based and capecitabine (CAP)-based chemoradiation (CRT) for locally advanced pancreatic cancer (LAPC). Here we present the long-term outcomes.\ud methods: Eligibility: histologically proven LAPC less than or equal to7 cm. Following 12 weeks of induction GEMCAP chemotherapy (three cycles: GEM 1000 mg m−2 days 1, 8, 15; CAP 830 mg m−2 days 1–21 q28 days) patients with stable/responding disease, tumour less than or equal to6 cm, and WHO Performance Status 0–1 were randomised to receive one cycle GEMCAP followed by CAP (830 mg m−2 b.d. on weekdays only) or GEM (300 mg m−2 weekly) with radiation (50.4 Gy per 28 fractions).\ud results: One-hundred fourteen patients (28 UK centres) were registered between 24 December 2009 and 25 October 2011, and 74 were randomised (CAP-RT=36; GEM-RT=38). At the time of this analysis, 105 of the 114 patients had died and the surviving 9 patients had been followed up for a median of 10.9 months (IQR: 2.9–18.7). Updated median OS was 17.6 months (95% CI: 14.6–22.7) in the CAP-CRT arm and 14.6 months (95% CI: 11.1–16.0) in the GEM-CRT arm (intention-to-treat adjusted hazard ratio (HR): 0.68 (95% CI: 0.38–1.21, P=0.185)); median progression-free survival (PFS) was 12.0 months (95% CI: 10.0–15.2) in the CAP-CRT arm and 10.4 months (95% CI: 8.8–12.7) in the GEM-CRT arm (intention-to-treat adjusted HR: 0.60 (95% CI: 0.32–1.14, P=0.120)). In baseline multivariable model, age greater than or equal to65 years, better performance status, CA19.9
- Published
- 2017
28. Investigating the poor outcomes of BRAF - mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials
- Author
-
Seligmann, JF, Fisher, D, Smith, CG, Richman, SD, Elliott, F, Brown, S, Adams, R, Maughan, T, Quirke, P, Cheadle, J, Seymour, M, and Middleton, G
- Subjects
neoplasms - Abstract
Background: To improve strategies for the treatment of BRAF-mutant advanced colorectal cancer (aCRC) patients we examined individual data from patients treated with chemotherapy alone in three randomised trials to identify points on the treatment pathway where outcomes differ from BRAF wild-types. Patients and Methods: 2530 aCRC patients were assessed from three randomised trials. End-points were progression free survival (PFS), response rate (RR), disease control rate (DCR), post-progression survival (P-PS) and overall survival (OS). Treatments included first-line oxaliplatin/fluorouracil (OxFU), and second-line irinotecan. Clinicians were unaware of BRAF-status Results 231 patients (9.1%) had BRAF-mutant tumours. BRAF-mutation conferred significantly worse survival independent of associated clinicopathological factors known to be prognostic. Compared with wild-type, BRAF-mutant patients treated with first-line OxFU had similar DCR (59.2% vs 72%; adjusted OR=0.76,p=0.24) and PFS (5.7 vs 6.3 months; adjusted HR=1.14, p=0.26). Following progression on first-line chemotherapy, BRAF-mutant patients had a markedly shorter P-PS (4.2 vs 9.2 months, adjusted HR=1.69,p6 months; OS=24.0 months), however 36.5% progressed rapidly through first-line chemotherapy and thereafter, with OS=4.7 months. Conclusions BRAF-mutant aCRC confers a markedly worse prognosis independent of associated clinicopathological features. Chemotherapy provides meaningful improvements in outcome throughout treatment lines. Post-progression survival is markedly worse and vigilance is required to ensure appropriate delivery of treatment after first-line progression.
- Published
- 2017
29. Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer
- Author
-
Weber, A, Drobnitzky, N, Devery, A, Bokobza, S, Adams, R, Maughan, T, and Ryan, A
- Subjects
Lung Neoplasms ,radiosensitizer ,Tumor Suppressor Proteins ,missense mutation ,Cell Cycle ,Homozygote ,Mutation, Missense ,Ataxia Telangiectasia Mutated Proteins ,Fibroblasts ,Immunohistochemistry ,Radiation Tolerance ,DNA damage response (DDR) ,ataxia-telangiectasia mutated (ATM) ,DNA-Binding Proteins ,non-small cell lung cancer (NSCLC) ,Phenotype ,Carcinoma, Non-Small-Cell Lung ,Cell Line, Tumor ,Mutation ,Humans ,RNA, Small Interfering ,Colorectal Neoplasms ,Signal Transduction ,Priority Research Paper - Abstract
Mutations in the Ataxia-telangiectasia mutated (ATM) gene are frequently found in human cancers, including non-small cell lung cancer (NSCLC). Loss of ATM function confers sensitivity to ionising radiation (IR) and topoisomerase inhibitors and may thus define a subset of cancer patients that could get increased benefit from these therapies. In this study, we evaluated the phenotypic consequences of ATM missense changes reported in seven NSCLC cell lines with regard to radiosensitivity and functionality of ATM signalling. Our data demonstrate that only 2/7 NSCLC cell lines (H1395 and H23) harbouring ATM missense mutations show a functional impairment of ATM signalling following IR-exposure. In these two cell lines, the missense mutations caused a significant reduction in ATM protein levels, impairment of ATM signalling and marked radiosensitivity. Of note, only cell lines with homozygous mutations in the ATM gene showed significant impairment of ATM function. Based on these observations, we developed an immunohistochemistry-based assay to identify patients with loss or reduction of ATM protein expression in a clinical setting. In a set of 137 NSCLC and 154 colorectal cancer specimens we identified tumoral loss of ATM protein expression in 9.5% and 3.9% of cases, respectively, demonstrating the potential utility of this method.
- Published
- 2016
30. The impact of routine assessment of information needs on patient outcomes
- Author
-
Al-Mohammadi, A, Salek, MS, Maughan, T, Nicholls, PJ, and Mason, M
- Published
- 2016
31. Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
- Author
-
Maughan, T, Adams, RA, Smith, CG, Seymour, MT, Wilson, R, Meade, AM, Fisher, D, Madi, A, Cheadle, J, and Kaplan, R
- Published
- 2016
32. Orbital lymphoproliferative lesions: A clinicopathological study of 15 cases
- Author
-
Boyde, A, Dojcinov, SD, Dawson, TW, Lane, C, Maughan, T, and Attanoos, RL
- Published
- 2016
33. A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS (RCTS) OF EGFR-TARGETED MONOCLONAL ANTIBODY (MAB) THERAPY IN ADVANCED COLORECTAL CANCER (ACRC): IMPACT OF K-RAS STATUS
- Author
-
Vale, C, Tierney, J, Meade, A, Fisher, D, Kaplan, R, Adams, R, Maughan, T, and Parmar, M
- Published
- 2016
34. THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED
- Author
-
Maughan, T, Wilson, R, Seymour, M, Meade, A, Fisher, D, Kenny, S, Smith, CG, Cheadle, JP, Kaplan, R, and Adams, R
- Published
- 2016
35. Pharmacoeconomic analysis of Capecitabine in the adjuvant setting. Results from the X-ACT trial comparing capecitabine with 5-FU/LV in patients with Dukes' C colon cancer
- Author
-
Douillard, J-Y, Twelves, C, McKendrick, J, Bertetto, O, Coxon, F, Diaz-Rubio, E, Dufour, P, Maughan, T, Scheithauer, W, and Burris, H
- Published
- 2016
36. Clinical impact of diagnostic discrepancies identified by central pathological review of lymphomas - A report of the All Wales Lymphoma Pathology Group
- Author
-
Dojcinov, SD, Attanoos, RL, O'Brien, CJ, Toy, L, Lester, J, Poynton, CH, and Maughan, T
- Published
- 2016
37. Establishing effective networks to support clinical cancer research: The Wales Cancer Trials Network
- Author
-
Branston, L, Maughan, T, Stuart, N, and Mason, MD
- Published
- 2016
38. ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS
- Author
-
Adams, R, Maughan, T, Smith, C, Seymour, M, Wilson, R, Meade, A, Fisher, D, Madi, A, Kenny, S, Wasan, H, Rogers, P, Hodgkinson, E, Jasani, B, Cheadle, J, and Kaplan, R
- Published
- 2016
39. Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed
- Author
-
Keating, MJ, Cazin, B, Coutré, S, Birhiray, R, Kovacsovics, T, Langer, W, Leber, B, Maughan, T, Rai, K, Tjønnfjord, G, Bekradda, M, Itzhaki, M, and Hérait, P
- Subjects
Adult ,Aged, 80 and over ,Male ,Salvage Therapy ,Cancer Research ,Leukemia, T-Cell ,Time Factors ,Antibodies, Neoplasm ,Antibodies, Monoclonal ,Antineoplastic Agents ,Middle Aged ,Opportunistic Infections ,Antibodies, Monoclonal, Humanized ,Hematologic Diseases ,Survival Rate ,Oncology ,Consumer Product Safety ,Humans ,Female ,Infusions, Intravenous ,Alemtuzumab ,Aged ,Retrospective Studies - Abstract
PURPOSE: We conducted a retrospective analysis to evaluate the safety and efficacy of Campath-1H, an anti-CD52 humanized monoclonal antibody, in previously treated T-prolymphocytic leukemia (T-PLL) patients in a compassionate-use program. PATIENTS AND METHODS: Seventy-six patients with T-PLL (including four chemotherapy-naive patients) received 3, 10, and 30 mg of Campath-1H on sequential days, followed by 30 mg three times weekly, as 2-hour intravenous infusions, for 4 to 12 weeks. RESULTS: Median patient age was 60 years (range, 35 to 84). Spleen liver, lymph node, and skin involvement were present in 64%, 40%, 54%, and 18% of patients, respectively. All tested patients had CD2, CD7, CD4, and/or CD8 positivity, whereas CD5 and CD3 were positive in 98% and 96% of tested patients, respectively. The objective response rate was 51% (95% confidence interval [CI], 40% to 63%), with a 39.5% complete response (CR) rate (95% CI, 28% to 51%). The median duration of CR was 8.7 months (range, 0.13+ to 44.4), and median time to progression was 4.5 months (range, 0.1 to 45.4) compared with 2.3 months (range, 0.2 to 28.1) after first-line chemotherapy. The median overall survival was 7.5 months (14.8 months for CR patients). The most common Campath-1H–related adverse events were acute reactions during or immediately after infusions. Fifteen infectious episodes occurred during treatment in 10 patients (13%), leading to treatment discontinuation in three. Eight patients experienced possibly related, late-onset infections. Severe thrombocytopenia and/or neutropenia occurred in six patients (8%), leading to treatment discontinuation in four. Two treatment-related deaths occurred. CONCLUSION: Campath-1H is an active drug in T-PLL patients for whom first-line therapy has failed. It has a favorable risk/benefit ratio and should be prospectively investigated in chemotherapy-naive patients.
- Published
- 2002
- Full Text
- View/download PDF
40. Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now
- Author
-
MacGregor, T, Maughan, T, and Sharma, R
- Abstract
Neoadjuvant chemoradiotherapy for locally advanced rectal cancer has been shown to decrease rates of local recurrence and more than double the rate of sphincter-preserving surgery. There is now compelling evidence that pathological complete response is an independent predictor of likelihood of local recurrence, distal metastases, disease-free and overall survival in locally advanced rectal cancer following neoadjuvant chemoradiotherapy. Pathological regression grading can therefore guide clinical decisions about salvage surgical strategies, adjuvant therapy and long-term surveillance. No universally recognised regression grading system currently exists for pathologists presented with resected tumour specimens following neoadjuvant chemoradiotherapy. The purpose of this review is to highlight the relevance of accurate tumour regression grading in achieving optimal clinical care for patients with rectal cancer.
- Published
- 2012
41. CETUXIMAB COMBINED WITH INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID AND OXALIPLATIN IN METASTATIC COLORECTAL CANCER: POOLED ANALYSIS OF COIN AND OPUS STUDY DATA
- Author
-
Taieb, J, Maughan, T, Bokemeyer, C, Van Cutsem, E, Brodowicz, T, Folprecht, G, Esser, R, Schlichting, M, and Tabernero, J
- Published
- 2012
42. High Tunnel Pepper Production
- Author
-
Maughan, T., Drost, D., Black, Brent, and Utah State University
- Subjects
high tunnel ,pepper ,horticulture ,High tunnels ,Agriculture ,peppers - Abstract
This publication provides information on growing high tunnel peppers including site preparation, site and irrigation management, and planting dates and spacing.
- Published
- 2012
43. Panitumumab in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer: Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification
- Author
-
Seymour, M, Brown, SR, Richman, S, Middleton, G, Maughan, T, Maisey, N, Hill, M, Olivier, C, Napp, V, and Quirke, P
- Published
- 2011
44. Ciclosporin in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer - Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification
- Author
-
Middleton, G, Brown, SR, Gwyther, S, Maughan, T, Wadsley, J, Chau, I, Richman, S, Olivier, C, Marshall, H, and Seymour, M
- Published
- 2011
45. Authors' reply
- Author
-
Seymour, M, Thompson, L, O'Mahony, S, Brewster, A, Wasan, H, and Maughan, T
- Published
- 2011
46. AGGRESSIVE VERSUS NON-AGGRESSIVE INITIAL TREATMENT
- Author
-
Maughan, T
- Published
- 2010
47. A NOVEL COLORECTAL CANCER SUSCEPTIBILITY SNP IN THE EIF3H PROMOTER INFLUENCES PATIENT SURVIVAL AND RESPONSE TO TREATMENT
- Author
-
Cheadle, J, Smith, C, Fisher, D, Maughan, T, Moskvina, V, Meade, A, West, H, and Kaplan, R
- Published
- 2010
48. A novel colorectal cancer susceptibility SNP in the EIF3F1 promoter influences patient survival and response to treatment
- Author
-
Smith, C, Fisher, D, Harris, R, Maughan, T, Idziaszczyk, S, Moskvina, V, Colley, J, Meade, A, Bonnet, C, West, H, Kaplan, R, and Cheadle, J
- Published
- 2010
49. THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS
- Author
-
Maughan, T, Adams, R, Smith, C, Seymour, M, Wilson, R, Meade, A, Fisher, D, Madi, A, Cheadle, J, and Kaplan, R
- Published
- 2010
50. INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS
- Author
-
Adams, R, Wilson, R, Seymour, M, Meade, A, Madi, A, Cassidy, J, Fisher, D, Kenny, S, Kaplan, R, and Maughan, T
- Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.